Scientists are literally turning back the clocks in our cells, with the first drugs about to go to human trials ...
Morning Overview on MSN
Aging immune cells may edit their own DNA to stay inflamed
As people grow older, their immune systems do not simply slow down, they often become locked into a simmering, ...
Money Talks News on MSN
Scientist claims humans could live 20,000 years with new technology
British scientist says humans could live 20,000 years through DNA reprogramming and cellular repair technology that ...
A research paper by scientists from Beijing Institute of Technology investigated the anti-tumor effect of millimeter waves ...
New research shows that a high-fat diet causes cellular damage that directly paves the way for liver cancer. The strain comes ...
Research into how a father’s choices — such as diet, exercise, stress, nicotine use — may transfer traits to his children has ...
Detailed price information for AI / ML Innovations Inc (AIMLF) from The Globe and Mail including charting and trades.
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ...
Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at ...
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback